Product review · Updated September 30, 2026
Obagi Pore Therapy review: the liquid label and the historical formula boundary
The January 2025 liquid record differs from an inactivated 2011 label in packager, contents and inactive declaration.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Obagi’s CLENZIderm M.D. Pore Therapy is a named salicylic liquid exfoliant within an acne-focused product range. A whole-product review needs more than its percentage or professional presentation. The current manufacturer description, a January 2025 posted label and an older inactivated record answer different parts of the identity question, and their bases should not be silently merged.
We read those official records on September 30, 2026. This review uses the 2025 Obagi Cosmeceuticals liquid label as its specified version and retains the 2011 OMP record as historical contrast. We did not inspect a purchased bottle, verify current stock or obtain an individual assessment through the manufacturer’s physician-navigation link. The public documentation does not establish a personal comfort outcome.
In this article
Pore Therapy is the particular liquid exfoliant
The manufacturer identifies CLENZIderm M.D. Pore Therapy as a 2% salicylic acid liquid exfoliant and positions it for normal and oily skin. Its pore and smoother-skin wording describes the marketed toner. This review does not apply a neighboring product’s attributes to Pore Therapy or turn the brand’s audience language into individual clearance. Manufacturer description.
The January 2025 label supplies a specific acne-treatment liquid record to pair with that description. A toner name, an acne ingredient and a professional-looking range can help identify an item without proving its comparative tolerability. The exact formula version remains important because a broadly familiar product name can persist across documents with materially different identifying details. Label identity.
January 2025 defines the chosen posted version
DailyMed identifies Obagi Cosmeceuticals as packager, January 1, 2025, as the update date and NDC 62032-612-04 as the label identifier. The principal panel describes a 5 fl oz, 148 mL bottle. These details define the record used here, not the contents of every container available under the same product name. Dated label and package.
The full inactive prose list includes chamomile flower extract, benzyl alcohol, fragrance, glycerin, menthol and SD alcohol 40-B among its named constituents. That declaration supplies a broader base than the retained manufacturer description alone. The combination-formula guide provides further reading about why the whole list matters without treating a named ingredient as a personal-effect prediction.
The inactivated 2011 record is not interchangeable
The older label is marked as containing an inactivated NDC and identifies OMP as packager. It was updated December 15, 2011, with NDC 62032-110-60 and a 118 mL bottle panel. Its inactive list names benzalkonium chloride, while the 2025 declaration names chamomile. The records therefore remain distinct. Historical label; 2025 declaration.
This contrast does not establish why the records differ, when every manufacturing change happened or which formula is in an unseen bottle. We do not merge their constituents into a composite product. The Stridex review offers another documentation reading destination; the link does not claim equivalent version histories, ingredients or clinical performance.
A toner description does not replace the full base
The manufacturer’s retained description names the 2% liquid and its intended pore-refining role but does not return a complete INCI list or net contents. The specified label supplies those broader formula and package details. It names fragrance, menthol and SD alcohol 40-B; these facts should not be replaced by an assumption that a toner must be alcohol-free. Product description; label base.
That is a boundary on what the records establish, not a claim that any one constituent determines irritation. It also avoids borrowing attributes from a different toner in the brand’s range. An ingredient declaration can identify the mixture while leaving its actual feel and comparative comfort untested by this review and unresolved in the acquired evidence.
The acne active and cautions belong to this liquid
The 2025 label declares salicylic acid 2% for acne treatment and preserves drying or irritation cautions involving other topical acne medication. It also contains a severe-irritation warning. These are parts of the exact liquid’s label, rather than optional footnotes that disappear because a product is presented within a professional skincare range. Active and warnings.
FDA’s Drug Facts explanation separates those warning fields from the active amount and inactive list. This review does not turn them into an application or combination plan. The Aveeno review is another independently considered product destination, with no implied equivalence of role or personal comfort between a toner and a moisturizer. Label context.
Find-a-physician navigation is not an assessment
The manufacturer page includes a Find a Physician navigation option under professional-guidance wording. Its presence establishes a public link, not that a clinician reviewed a particular reader, cleared this exact formula or responded to a concern. We did not enter a consultation or evaluate a clinical handoff through that navigation. Professional-navigation record.
AAD’s general discussion recognizes that salicylic acne treatments may dry or irritate skin. It is not a trial of this toner or a substitute for individual evaluation. The mature dry-skin guide offers broader context about separating comfort questions from diagnosis. Professional presentation and product identity remain different from a documented personal assessment. AAD explanation.
The dated liquid is the fair unit of comparison
Pore Therapy’s manufacturer record and specified 2025 label establish the named liquid, declared active and a particular full base. The 2011 label explains why historical search results require care. Neither record verifies a current purchased package, independent batch assay or controlled comfort advantage over another product. Current description; specified version.
The product comparison offers a further reading path about format and evidence. For Obagi, a fair account keeps label date, packager, volume and inactive differences visible. It does not borrow professional authority, collapse two historical bases into one or turn a well-defined product record into a claim that the toner is the best clinical choice.
Sources behind this reading
- Obagi CLENZIderm M.D. Pore Therapy: current toner description ↗Official manufacturer public product/brand record; source-specific scope · Checked September 30, 2026
- DailyMed: Obagi Cosmeceuticals CLENZIderm Pore Therapy, January 1, 2025 label ↗Official packager labeling record; dated and package-version limits · Checked September 30, 2026
- DailyMed: OMP CLENZIderm Pore Therapy, inactivated December 15, 2011 label ↗Official packager labeling record; dated and package-version limits · Checked September 30, 2026
- FDA: The Over-the-Counter Drug Facts Label ↗Regulator explanation of OTC label fields · Checked September 30, 2026
- American Academy of Dermatology: moisturizer and acne treatment ↗Medical society patient guidance · Checked September 30, 2026